cetirizine oral / Generic mfg. - LARVOL DELTA

Impact of Varied Antihistamine Premedication on Rituximab Infusion Reaction Rates (HOPA 2026) - "Standard premedication includes acetaminophen, corticosteroids, and antihistamines to mitigate this risk.1-5 Diphenhydramine, a first-generation H1 antagonist, is commonly used despite its sedating side effects. Recent studies suggest second-generation agents such as loratadine or cetirizine offer similar protection against infusion reactions with less sedation, potentially improving tolerability and safety... We hypothesize that the incidence of infusion-related reactions during or after the initial rituximab infusion will not differ between patients receiving dual H1 and H2 antagonist premedication compared to those receiving an H1 antagonist alone. This study aims to determine whether dual antagonist premedication offers a significant benefit in preventing rituximab infusion-related reactions."

B Cell Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma

Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer (IMMUNOLOGY 2026) - "Non-targeted metabolomics analysis using LC-MS identified specific activation of the histidine metabolism pathway, with elevated levels of the key metabolite Cetirizine N-Oxide potentially contributing to enhanced immune activity. These results demonstrate a promising "microbiome-immune" dual-targeting strategy for colon cancer with clinical translational potential."

Clinical • Immunomodulating • Late-breaking abstract • Colon Cancer • Colorectal Cancer • Immunology • Oncology • Solid Tumor • BCL6 • CD8 • PTPRC

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: University of Miami

New P3 trial • CNS Disorders • Multiple Sclerosis

THE HEART UNDER ATTACK TWICE: ANAPHYLAXIS AND VF ARREST IN MASTOCYTOSIS REVEALING KOUNIS SYNDROME (ACC 2026) - "Case: A 45-year-old woman with biopsy-proven mastocytosis developed rash, dyspnea, and hypotension after taking ibuprofen...Tenecteplase was given for presumed STEMI...She was discharged on amlodipine, cetirizine, and epinephrine pens with strict trigger avoidance... In mastocytosis, anaphylaxis can precipitate KS with STEMI and VF despite normal coronaries. Management should focus on preventing anaphylaxis, utilizing vasodilator therapy, and exercising caution when using antithrombotics or beta-blockers."

Acute Coronary Syndrome • Cardiovascular • Hypotension • Pulmonary Disease

CORONARY ARTERY BYPASS GRAFTING IN COLD-INDUCED URTICARIA USING PREMEDICATION AND STRICT THERMAL MANAGEMENT: A CASE REPORT (ACC 2026) - "Premedication included fexofenadine, cetirizine, famotidine, montelukast, prednisolone, and diphenhydramine. Omalizumab was administered preoperatively. Epinephrine pen was available during the procedure... CABG can be safely accomplished in patients with cold-induced urticaria by combining structured premedication with vigilant thermal control. This case adds intraoperative temperature and cardioplegia parameters demonstrating safe on-pump CABG with moderate systemic cooling, cold cardioplegia, and elimination of topical ice, supported by structured premedication."

Case report • Clinical • Cardiovascular • Dermatology • Dyslipidemia • Hypertension • Hypotension • Immunology • Nicotine Addiction • Peripheral Arterial Disease • Urticaria

Dermatomyositis Misdiagnosed as Atopic Dermatitis: A Case Report with Ovarian Cancer Association (AAD 2026) - "She had previously consulted three dermatologists, all diagnosing atopic dermatitis, and was treated with cetirizine, hydroxychloroquine, and sunscreen without improvement...Systemic corticosteroids and methotrexate were initiated with clinical improvement... Dermatomyositis is a multisystemic disease that requires thorough clinical evaluation and multidisciplinary care. Dermatology must not lose its essence in clinical practice. Overemphasis on aesthetics risks overshadowing its fundamental role in diagnosing systemic diseases such as DM and related paraneoplastic syndromes."

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatomyositis • Dermatopathology • Immunology • Myositis • Oncology • Ovarian Cancer • Solid Tumor • CD8

Case report: Cetirizine-induced fixed drug eruption in a pediatric patient (AAD 2026) - "We discontinued cetirizine, switched to desloratadine, and educated them about FDE. The final diagnosis was FDE due to cetirizine. This is the first case of FDE caused by cetirizine in a pediatric patient."

Case report • Clinical • Allergic Rhinitis • Immunology • Inflammation • Pediatrics • Pruritus

Application of paediatric cetirizine PBPK model to guide precision medicine and understand renal P-glycoprotein ontogeny. (PubMed, Br J Clin Pharmacol) - "Utilizing PBPK modelling and simulation, this study elucidated P-gp ontogeny and recommended the optimal cetirizine dosage regimen for children across all age groups."

Journal • Allergic Rhinitis • Dermatology • Immunology • Inflammation • Pediatrics • Urticaria

TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND DIRECT MEDICAL COSTS OF CHRONIC URTICARIA IN CHINA: A REAL-WORLD STUDY (ISPOR 2026) - "Over 90% received second-generation antihistamines, mainly ebastine, levocetirizine, and cetirizine. Omalizumab was used by 573 (Tianjin) and 399 (Xiamen) patients, primarily at 300 mg... This real-world study provides comprehensive insights into CU treatment patterns, healthcare resource utilization, and economic burden in China, informing decision-making for CU management and healthcare resource allocation."

Clinical • HEOR • Real-world • Real-world evidence • CNS Disorders • Dermatology • Dermatopathology • Immunology • Infectious Disease • Respiratory Diseases • Sleep Disorder • Urticaria

COST-EFFECTIVENESS OF REMIBRUTINIB FOR MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA IN THE U.S. (ISPOR 2026) - "This study aims to evaluate the cost-effectiveness of remibrutinib compared to the standard of care (SOC) second-generation antihistamine from a healthcare sector perspective in the U.S. We constructed a Markov model to estimate 10-year and 24-week outcomes among patients with moderate to severe CSU, with the interventions being either remibrutinib with cetirizine or cetirizine alone. Based on this model, remimbrutinib is not cost-effective with a WTP of $150,000 per QALY."

Cost effectiveness • HEOR • Chronic Spontaneous Urticaria • Dermatology • Immunology • Inflammation • Urticaria

BEYOND THE LABEL: OFF-LABEL AND UNLICENSED RESPIRATORY DRUG PRESCRIBING IN PEDIATRIC OUTPATIENTS - A PATIENT SAFETY PERSPECTIVE FROM PAKISTAN (ISPOR 2026) - "The most common medication category in off-label prescribing was antihistamines (41.9%), of which cetirizine was prescribed off-label in 24% of patients... This study highlights the extent of Off-label respiratory drug prescribing in pediatric outpatients. Prescribing off-label and unlicensed respiratory drugs is ubiquitous among pediatric patients, with the potential for untoward reactions. There is a need to develop the existing and new scientific evidence by involving the pediatric population in clinical trials."

Clinical • Allergic Rhinitis • Immunology • Inflammation • Pediatrics • Respiratory Diseases

HiHat trial (clinicaltrialsregister.eu) - P1/2 | N=50 | Not yet recruiting | Sponsor: Region Uppsala

New P1/2 trial • CNS Disorders • Multiple Sclerosis

Use of Unsupervised Learning to Identify Patients with Chronic Spontaneous Urticaria from Electronic Health Record Data (AAAAI 2026) - "Medications for treatment include H1 antihistamines, and anti-IgE omalizumab for unresponsive patients...Of the top 10 features that differentiated the clusters best, eight were medications (prednisone, cetirizine, diphenhydramine, epinephrine, methylprednisolone, famotidine, dexamethasone, fexofenadine), one laboratory test (Antinuclear Antibody) and one comorbidity (chronic obstructive pulmonary disease)...Medications were the key features that differentiated between subgroups of patients with urticaria. This method shows promise in identifying patients most in need of advanced therapeutic interventions including immunosuppressants."

Clinical • Chronic Obstructive Pulmonary Disease • Chronic Spontaneous Urticaria • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

Pharmacoeconomic Evaluation of Allergic Rhinitis in a Northeastern Mexican Population (AAAAI 2026) - "Cetirizine and intranasal fluticasone were the most used medications. Conclusions Allergic rhinitis represents a significant financial burden in Mexico, with nearly one-third of the minimum wage required monthly for adequate management. The awareness of costs could help increase treatment adherence, identify better treatment options, and develop conscientious healthcare policies."

Clinical • HEOR • Late-breaking abstract • Allergic Rhinitis • Immunology • Inflammation

The effects of oral second-generation antihistamines on psychomotor, cognitive, and academic performance: A systematic review (AAAAI 2026) - "Search terms included oral second-generation antihistamines approved for use in the United States and Canada, specifically cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine, with the terms psychomotor, cognitive, and academic performance. Varying effects were found across these categories. Understanding these outcomes will better inform patient care via appropriate selection of antihistamines to minimize disruption on daily activities."

Review

Emergency Department Management of Anaphylaxis in Pediatric Patients (AAAAI 2026) - "Methods A single educational session was held for ED providers focusing on preferential use of second-generation antihistamines, post-epinephrine observation times, reducing use of systemic steroids in the ED and at discharge, reducing use of H2 blockers...Patients seen post-intervention were administered less diphenhydramine (17%, p = 0.001), famotidine (33%, p <0.001), or steroids (28%, p <0.001), and more cetirizine (13%, p = 0.002)...We found appropriately increased use of second-generation antihistamines and decreased use of H2 blockers and steroids in the ED. Length of stay shortened significantly though unchanged steroid prescribing at discharge highlights the need for further intervention."

Clinical • Pediatrics

Increased Second-Generation Antihistamine Use via a Multicomponent Quality-Improvement Initiative (AAAAI 2026) - "Interventions included survey distribution assessing baseline prescribing and guideline knowledge (February 2024), Pyxis/triage standing order update from diphenhydramine to cetirizine (October 2024), ED division-wide education (January 2025), and publication of an urticaria/angioedema clinical pathway with an accompanying order set (February 2025). SPC analysis demonstrated special-cause variation, and ITS regression confirmed an immediate level increase and sustained slope change. Conclusions This QI initiative significantly increased second-generation antihistamine prescribing and reduced diphenhydramine-only use, demonstrating that system-level interventions can shift prescribing toward guideline-concordant practice."

Cardiovascular • Dermatology • Dermatopathology • Immunology • Urticaria

299IG301: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) (clinicaltrialsregister.eu) - P2/3 | N=201 | Recruiting | Sponsor: Biogen Idec Research Limited

New P2/3 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study. (PubMed, Br J Clin Pharmacol) - "In this large nationwide cohort of patients with allergic rhinitis, second-generation antihistamines with higher vs. lower sedative potential showed no difference in injury risk during Japan's pollen season."

Journal • Retrospective data • Allergic Rhinitis • Anesthesia • Immunology • Inflammation

Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer. (PubMed, Int Immunopharmacol) - "Non-targeted metabolomics analysis using LC-MS identified specific activation of the histidine metabolism pathway, with elevated levels of the key metabolite Cetirizine N-Oxide potentially contributing to enhanced immune activity. Mechanistic studies further revealed that the triple therapy suppresses the activity of the Bcl6 regulatory network, thereby reducing the immunosuppressive function of Tregs and destroying the immunosuppressive interplay between myeloid immune cells and Tregs. These results demonstrate a promising "microbiome-immune" dual-targeting strategy for colon cancer with clinical translational potential."

Journal • Colon Cancer • Colorectal Cancer • Immunology • Oncology • Solid Tumor • BCL6 • CD4

Exploring lactoferrin as an innovative covalently immobilized chiral selector for the selective separation of pharmaceutical enantiomers using HPLC. (PubMed, Anal Chim Acta) - "HPLC remains the primary choice for all pharmaceutical research, as it offers higher sensitivity, reliability, and reproducibility. This work introduces LF as a novel, multifunctional CS for HPLC, covalently immobilized for the first time, expanding the toolbox of protein-based chiral stationary phases. Moreover, the study also offers a critical insight into the limitations of relying solely on computational predictions, empirically demonstrating that solvent effects can override binding affinities, a phenomenon not captured by standard docking simulations."

Journal

Efficacy and safety of oral antihistamines for allergic rhinitis: Network meta-analysis. (PubMed, J Allergy Clin Immunol Pract) - "Although some OAH seem to be more efficacious than others, most differences between individual second-generation medications are trivial or small. In addition, we did not find relevant differences in the safety profiles of second-generation OAH."

Journal • Retrospective data • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Real-World Infusion Experience with Ublituximab in ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab (ACTRIMS Forum 2026) - P | "In Phase 3 studies (ULTIMATE I and II) ublituximab demonstrated significant reduction in MS disease activity versus teriflunomide...About 32% were treatment-naïve at the start of ENABLE and 28% transitioned to ublituximab from a B-cell therapy- ocrelizumab, ofatumumab or rituximab, followed by 19% from natalizumab...Premedication included corticosteroids (methylprednisolone, 88.5% of patients), antipyretic (paracetamol, 79.8%), and antihistamines (diphenhydramine, 77.6%; cetirizine, 12.8%)... ENABLE patients experienced lower IRRs at the first dose compared to ULTIMATE. IRRs continued to decrease at subsequent doses, and infusions were completed within the specified time. Overall, ublituximab infusions were well-tolerated in this real-world observational study."

Clinical • Observational data • P4 data • Real-world • Real-world evidence • CNS Disorders • Dermatology • Multiple Sclerosis • Pruritus

Prevention of Subsequent L-Asparaginase Hypersensitivity in Children Through Premedication: A Single-Center Experience. (PubMed, J Pediatr Pharmacol Ther) - "In resource-limited settings, our premedication protocol demonstrated potential for safely enabling continued native E. coli L-asparaginase therapy in children with a history of severe hypersensitivity reactions, thus potentially improving access to chemotherapy treatment."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics

Improving Use of Oral Antihistamines in a Children's Hospital. (PubMed, Pediatrics) - "Using the Model for Improvement, we reduced FGA use and increased cetirizine use in the PED and inpatient setting."

Journal • Pediatrics